Study shows frequently used serology test may not detect antibodies that could confirm protection against reinfection of COVID-19

SARS-CoV-2 antibody serology assays developed by MD Anderson researchers accurately detect neutralizing antibodies
University of Texas M. D. Anderson Cancer Center

Newswise — HOUSTON ― Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may often only indicate exposure to the virus, not protections against reinfection. 

The results, published today in JCI Insight, highlight findings from a quantitative serological enzyme-linked immunosorbent assay (ELISA) using SARS-CoV-2 S-RBD and N-protein for the detection of circulating antibodies in 138 serial serum samples from confirmed COVID-19 hospitalized patients and 464 healthy and non-COVID-19 serum samples that were collected between June 2017 and June 2020.

Results showed that 3% of healthy and non-COVID-19 samples collected during the pandemic in Houston were positive for the N-protein antibody, but only 1.6% of those had the S-RBD antibody. Of samples with the S-RBD antibody, 86% had neutralizing capacity – meaning they could prevent reinfection of COVID-19, but only 74% of samples with N-protein had neutralizing capacity. When positive for both, 96.5% exhibited neutralizing capacity.    

“These findings suggest that detection of N-protein binding antibodies does not always correlate with presence of S-RBD neutralizing antibodies, and that the presence of the S-RBD antibody is the best indicator of any potential protection against reinfection,” said senior author Raghu Kalluri, M.D., Ph.D., professor and chair of Cancer Biology. “We caution against the extensive use of N-protein based serology testing for determination of potential COVID-19 immunity, and we believe that accurate and reliable S-RBD serological testing is needed to carefully identify individuals with neutralizing antibodies in order to help advance recovery efforts around the globe.”

At present, some commercially available serological tests confirm only the presence antibodies to the N-protein, with over 200 commercial and hospital laboratory testing facilities currently using these tests.  While these tests indicate exposure to the virus, they do not seem to suggest immunity to reinfection.  These findings reiterate the need to educate on what an antibody test result mean for each patient, and that public health efforts should focus on ways to encourage patients to continue vigilant safety precautions even with the presence of N-protein antibodies.

“In addition to serological assessment of the general population, we are hopeful these results will aid in rapid assessment of the efficacy of vaccine candidates as they are translated into the broader population,” said lead author Kathleen McAndrews, Ph.D., postdoctoral fellow in Cancer Biology.

Luis L. Ostrosky-Zeichner, M.D., and Ramesh Papanna, M.D., of The University of Texas Health Science Center at Houston (UT Health) McGovern Medical School, contributed some samples to the study. A full list of co-authors can be found in the paper.

 

- 30 -

 

About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

       

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 3395
Newswise: Historical Racial & Ethnic Health Inequities Account for Disproportionate COVID-19 Impact
22-Sep-2020 4:00 PM EDT
Historical Racial & Ethnic Health Inequities Account for Disproportionate COVID-19 Impact
American Thoracic Society (ATS)

A new Viewpoint piece published online in the Annals of the American Thoracic Society examines the ways in which COVID-19 disproportionately impacts historically disadvantaged communities of color in the United States, and how baseline inequalities in our health system are amplified by the pandemic. The authors also discuss potential solutions.

Released: 24-Sep-2020 5:05 PM EDT
In-person college instruction leading to thousands of COVID-19 cases per day in US
University of Washington

Reopening university and college campuses with primarily in-person instruction is associated with a significant increase in cases of COVID-19 in the counties where the schools are located.

Newswise: Some Severe COVID-19 Cases Linked to Genetic Mutations or Antibodies that Attack the Body
Released: 24-Sep-2020 3:25 PM EDT
Some Severe COVID-19 Cases Linked to Genetic Mutations or Antibodies that Attack the Body
Howard Hughes Medical Institute (HHMI)

Two new studies offer an explanation for why COVID-19 cases can be so variable. A subset of patients has mutations in key immunity genes; other patients have auto-antibodies that target the same components of the immune system. Both circumstances could contribute to severe forms of the disease.

access_time Embargo lifts in 2 days
Embargo will expire: 25-Sep-2020 6:30 PM EDT Released to reporters: 24-Sep-2020 3:20 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Sep-2020 6:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

17-Sep-2020 1:15 PM EDT
Accuracy of commercial antibody kits for SARS-CoV-2 varies widely
PLOS

There is wide variation in the performance of commercial kits for detecting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published September 24 in the open-access journal PLOS Pathogens by Jonathan Edgeworth and Blair Merrick of Guy’s and St Thomas’ NHS Foundation Trust, Suzanne Pickering and Katie Doores of King's College London, and colleagues. As noted by the authors, the rigorous comparison of antibody testing platforms will inform the deployment of point-of-care technologies in healthcare settings and their use in monitoring SARS-CoV-2 infections.

24-Sep-2020 9:25 AM EDT
Loneliness levels high during COVID-19 lockdown
Newswise Review

During the initial phase of COVID-19 lockdown, rates of loneliness among people in the UK were high and were associated with a number of social and health factors, according to a new study published this week in the open-access journal PLOS ONE by Jenny Groarke of Queen’s University Belfast, UK, and colleagues.

Newswise: Genetic, immunological abnormalities in Type I interferon pathway are risk factors for severe COVID-19
24-Sep-2020 12:35 PM EDT
Genetic, immunological abnormalities in Type I interferon pathway are risk factors for severe COVID-19
Uniformed Services University of the Health Sciences (USU)

Individuals with severe forms of COVID-19 disease can present with compromised type I interferon (IFN) responses based on their genetics, according to results published in two papers today in the journal Science. Type I IFN responses are critical for protecting cells and the body from more severe disease after acute viral infection.

Newswise: Talking Alone: Researchers Use Artificial Intelligence Tools to Predict Loneliness
Released: 24-Sep-2020 1:45 PM EDT
Talking Alone: Researchers Use Artificial Intelligence Tools to Predict Loneliness
University of California San Diego Health

A team led by researchers at University of California San Diego School of Medicine has used artificial intelligence technologies to analyze natural language patterns to discern degrees of loneliness in older adults.


Showing results

110 of 3395

close
1.55996